Additionally, OVs have been engineered to enhance their DC-activating capacity by expressing cytokines (e.g., GM-CSF), aiming to localize immune activation to the tumor site, enhance efficacy, and minimize systemic toxicity. The gene discussed is CSF2; the disease is neoplasm.